Trials / NCT03602820
Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)
Underway, not enrolling Observational Natural history / observational
- Sponsor
- Genentech, Inc.
- Treatment
- AAV2-hRPE65v2
- Gene
- RPE65
- Conditions
- Inherited Retinal Dystrophy Due to RPE65 Mutations
- Ages
- Any to no upper limit
- Enrollment
- 41 participants
- Started
- 2015-06
- Main results expected
- 2030-01
- Results posted
- Not yet
- Record last updated
- 2026-08-19
What the study is testing
Multi-site, non-randomized, observational study, for up to 15 years after subretinal AAV2-hRPE65v2 administration for each subject. The study is a non-interventional, follow-up study of subjects who participated in previous AAV2-hRPE65v2 gene therapy clinical trials.
Where it runs
No sites listed yet.